SEHK:1801Biotechs
Innovent Biologics (SEHK:1801), Why Is It Back In The Spotlight?
Innovent Biologics (SEHK:1801) caught investor attention after reporting product revenue of over CN¥4.3b for Q2 2026 and more than CN¥8.2b for the first half, supported by its dual engine growth strategy.
See our latest analysis for Innovent Biologics.
Those revenue headlines have arrived alongside firm share price momentum, with Innovent Biologics delivering a 30 day share price return of 8.66% and a 90 day share price return of 21.73%, while the three year total shareholder return of...